Open AccessClinical benefit for clinical sequencing using cancer panel testing
Author(s) -
Satoshi Nishimura,
Atsushi Sugimoto,
Shuhei Komatsu,
Shingo Togano,
Kenji Kuroda,
Yasutake Yamamoto,
M. Yamauchi,
Toshiyuki Sumi,
Hiroyasu Kaneda,
Tomoya Kawaguchi,
Mototsugu Kato,
Mizuki Tagami,
Naoto Oebisu,
Manabu Hoshi,
Kenjiro Kimura,
Shoji Kubo,
Kazuya Muguruma,
Tsutomu Takashima,
Masaichi Ohira,
Masakazu Yashiro
Publication year - 2021
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0247090
Subject(s) - kras , medicine , clinical trial , dna sequencing , genetic testing , cancer , targeted therapy , oncology , genomic sequencing , bioinformatics , gene , biology , genetics , genome , colorectal cancer
Background Clinical sequencing using a panel of genes has recently been applied worldwide for patients with refractory solid tumors, but the significance of clinical sequencing using gene panel testing remains uncertain. Here we sought to clarify the feasibility and utility of clinical sequencing in the treatment of refractory tumors at our hospital. Methods A total of 39 patients with advanced solid tumors treated at our hospital between 2018 and 2020 were enrolled in the clinical sequencing. Among them, we identified 36 patients whose tissue samples were of suitable quality for clinical sequencing, and we analyzed the genomic profiles of these tumors. Results Pathogenic alterations were detected in 28 (78%) of the 36 patients. The most common mutation was TP53 (55%), followed by KRAS (22%), and the highest frequency of gene amplification was ERBB2 (17%). Nine of the 36 patients were identified as candidates for novel molecular-targeted therapy based on their actionable gene alterations, but only one case ended up receiving novel targeted therapy following the genetic tests. Conclusions Our current results suggested that clinical sequencing might be useful for the detection of pathogenic alterations and the management of additional cancer treatment. However, molecular target based on actionable genomic alteration does not always bridge to subsequent therapy due to clinical deterioration, refusal for unapproved drug, and complexity of clinical trial access. Both improved optimal timing of clinical sequencing and a consensus about its off-label use might help patients receive greater benefit from clinical sequencing.